ADR Biomedical Holdings
3750.TInformation & Communication
Filed as FRACTALE Corporation (2022-06–2022-06), Cytori Cell Research Institute,Inc. (2022-08–2025-11), ADR120S, Inc. (2025-11–2026-06)
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥51m | ¥122m | ¥1.6bn | ¥2.1bn | ¥1.3bn | ¥1.4bn |
| Operating income | −¥906m | −¥807m | −¥773m | −¥794m | −¥462m | −¥732m |
| Ordinary income | −¥923m | −¥865m | −¥907m | −¥862m | −¥418m | −¥746m |
| Net income (owners) | −¥397m | −¥2.1bn | ¥138m | −¥1.1bn | −¥78m | −¥832m |
| Total assets | ¥368m | ¥3.5bn | ¥5.8bn | ¥14.1bn | ¥16.0bn | ¥14.9bn |
| Net assets / equity | ¥22m | ¥631m | ¥2.8bn | ¥2.7bn | ¥3.7bn | ¥3.5bn |
| Operating cash flow | −¥785m | −¥987m | −¥1.2bn | −¥40m | −¥188m | −¥83m |
| EPS (basic) | ¥-44.46 | ¥-239.7 | ¥15.47 | ¥-118.71 | ¥-8.79 | ¥-101.64 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 6
| Period | Form | Figures |
|---|---|---|
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 49 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 73 figures · EDINET |
| 2022-04-01 → 2023-03-31 | AnnualAmended | 201 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 47 figures · EDINET |
| 2022-04-01 → 2023-03-31 | AnnualAmended | 201 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 201 figures · EDINET |
23 more reports are still being processed.
Segments · FY ended 2025-03
| Segment | External sales | Profit |
|---|---|---|
| Medical Asset Managemet | ¥96m | −¥442m |
| Real Asset Management | ¥27m | −¥91m |
| Other segments | — | −¥274m |
| Total | ¥122m | −¥533m |
Segment names from EDINET member IDs; not mapped to a common taxonomy.